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MENYELESAIKAN KESAN ANDROGRAPHOLIDE PADA HMGCR 




Kanser payudara adalah pertumbuhan sel-sel malignan yang tidak terkawal 
dalam tisu payudara. Ia adalah jenis kanser kedua yang paling lazim di kalangan wanita 
dari segi kadar kematian dan insiden dengan anggaran tahunan kes didiagnosis melebihi 
1.5 juta. Kanser payudara tiga kali ganda adalah subtipe kanser payudara yang tidak 
menyatakan mana-mana tiga reseptor PR, ER dan HER2 dan terdiri daripada 15% 
daripada semua kes kanser payudara. Andrographis paniculata tumbuhan asalnya 
dijumpai di Malaysia, India dan banyak negara Asia Tenggara, dan secara tradisinya 
digunakan penduduk tempatan untuk merawat penyakit seperti demam, disentri, 
diabetes, obesiti dan malaria. Komponen bioaktif utamanya dipanggil. 
Andrographolide. Andrographolide mempunyai kesan anti-kanser pada 
pelbagai jenis kanser. Pada kanser payudara, kajian telah membuktikan bahawa ia 
mempunyai kesan anti-metastatik anti-proliferatif pada sel-sel kanser tetapi tidak 
mempunyai kesan pada sel-sel sel payudara biasa.  
3-Hydroxy-MethylGlutaryl Coenzyme-A (HMGCR) adalah enzim 
(glikoprotein) mempunyai peranan penting dalam proses biosintesis kolesterol 
kolesterol melalui jalur mevalonate. 
  Blotting Barat digunakan untuk menganalisis tahap ekspresi protein HMGCR 
di MDA-MB-231 sel selepas rawatan dengan 100mM Andrographolide dalam masa 
bergantung (4 jam, 24 jam dan 48 jam). 
Inhibisi proliferasi sel dan peraturan pergerakan protein HMGCR diperhatikan 
dalam sel yang dirawat dengan 100mM Andrographolide dalam masa yang bergantung 
xi 
 
pada masa (4hrs, 24 jam dan 48hrs) apabila dibandingkan dengan sel yang dirawat 
dengan DMSO sahaja. 
Andrographolide mempamerkan kesan antikanser pada sel-sel kanser payudara 































INVESTIGATING THE EFFECT OF ANDROGRAPHOLIDE ON HMGCR 




 Breast cancer is the uncontrolled malignant cellular growth in the tissues of 
the breast. It is the second most prevalent type of cancer among women in terms of 
mortality rates and incidents with annual approximation of diagnosed cases exceeds 
1.5 million. Triple-Negative Breast Cancer is a subtype of breast cancer that does not 
express any of the three receptors PR, ER and HER2 and comprises 15% of all breast 
cancer cases.   Andrographis paniculata a plant originally found in Malaysia, India 
and many Southeast Asia countries, and traditionally used by locals to treat diseases 
like fever, dysentery, diabetes, obesity and malaria. Its major bioactive compound is 
called Andrographolide. Andrographolide has anti-cancer effect on various types of 
cancer. On breast cancer, studies have proven that it has anti-proliferative anti-
metastatic effects on cancerous cells but has no effect on normal breast cell lines. 3-
Hydroxy-MethylGlutaryl Coenzyme-A (HMGCR) is an enzyme (glycoprotein) has a 
significant role in the process of cholesterol biosynthesis of cholesterol through the 
mevalonate pathway.  
 Western Blotting was used to analyze the HMGCR protein expression levels 
in MDA-MB-231 cells after treatment with 100mM of Andrographolide in time-
dependent manner (4hrs, 24hrs and 48hrs).    
Inhibition of cellular proliferation and down regulation of HMGCR protein 
expression was observed in cells treated with 100mM of Andrographolide in time-
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dependent manner (4hrs, 24hrs and 48hrs) when compared with cells treated with 
only DMSO.   
Andrographolide exhibited anticancer effect on Triple-Negative Breast Cancer 







1.1 Background of the study 
 
Breast cancer is the formation of malignant tumor within the normal tissues of the 
breast a shape of lumps. Statistically, it is the second type of cancer that cause high 
mortality rates among women worldwide and it is commonly diagnosed among them 
as well Siegel et al. (2017). In Malaysia, a women’s odd of getting breast cancer are 1 
in every 35 (Malay ethnicity), 1 in 22 (Chinese ethnicity) and 1 in 24 (Indians ethnicity) 
(Azizah, 2015). Not only in women, men are also at risk of developing breast cancer 
(about 1 in 1000 men will develop breast cancer in their life).  
Histopathological classification divides breast cancer into four types: basal-like, 
human epidermal growth factor receptor 2 (HER2), luminal A and B (Cho, 2016). On 
the other hand classification based on immunohistochemistry (IHC) classify breast 
cancer into  hormone receptor positive (PR+/ER+), HER+ and Triple-Negative Breast 
Cancer (TNBC) (Sun et al., 2017). 
Triple-Negative Breast Cancer (TNBC) is defined as a type of breast cancer in 
which the cancerous cells that lacks the expression of progesterone, estrogen and HER2 
receptors when measured with IHC. It is the most aggressive type of breast cancer, due 
to its short overall survival, distant recurrences (after the diagnosis in 3 years) and the 
absence of hormone receptors and no overexpression of HER2 (Collignon et al., 2016).  
Andrographis paniculata also known as the king of bitters, a plant native in India, 
Malaysia, Thailand and China. In Malaysia it is known as Hempedu bumi (Jayakumar 
et al., 2013). A. paniculata traditionally used to treat upper respiratory infection, flu 
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and sore throat. The major bioactive components of this plant known as 
Andrographolide. Andrographolide possesses anti-asthma, anti-stroke, anti-diabetic, 
anti-viral, anti-HIV and anti-inflammatory effects (Jayakumar et al., 2013). Several 
studies suggest that andrographolide has shown to have anti-cancer activity against 
various types of cancer cell lines including lung cancer, leukemia, melanoma and breast 
cancer (Shi et al., 2008a). A study reported that andrographolide inhibited the 
proliferation and migration of breast cancer cells and it induced apoptosis through 
caspase-independent pathway as well as the induction of cell cycle arrest at the G2/M 
(Kumar et al., 2012b)   
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is an important enzyme 
which has a significant role in the process of cholesterol biosynthesis through the 
mevalonate pathway (Sharpe and Brown, 2013). HMGCR act as a rate limiting enzyme 
which responsible for formation of mevalonate from 3-hydroxy-3-methyl-glutaryl-CoA 
(HMG-CoA)  (Hwang et al., 2016).  
 
1.2 Significance of the study 
 
Current breast cancer treatment strategies are considered harsh and invasive. Thus, the 
urge for seeking alternative remedies such as medicinal plants is needed. The current 
study evaluates the anti-cancer effect of a plant called Andrographis paniculate on 






1.3 Objectives of the study  
 
(a)       Determine the anti-cancer activity of Andrographolide compound extracted from 
Andrographis paniculata on Triple-Negative Breast Cancer cell line (MDA-MB-231).  
 (b) Determining the effect of Andrographolide on the expression level of HMGCR 
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2.1 Genomic Instability and Cancer 
 
Impaired and unstable genes are the causative agents of cancer. According to 
(Yao and Dai, 2014) the instability of the genes are considered the trade mark for most 
occurring cancer. Genomic instability is basically a spontaneous change in the genome 
of the cell obtained from the same ancestral precursors (Tubbs and Nussenzweig, 2017). 
In a normal healthy cell, the genomic stability is controlled by molecular mechanism. 
This particular mechanism in cancer cell is damaged beyond repair which leads to the 
mutation in the cell and these mutation are accumulated through time resulting in 
defected cellular mechanism (Tubbs and Nussenzweig, 2017). Genomic instabilities 
may occur due to microsatellite instability (MIN) with the mutator phenotype and 
chromosomal instability (CIN) with gross chromosomal changes (Raptis and Bapat, 
2006)  microsatellite instability (MIN) happens when there are alterations in the short 
repeat stretches of coding and non-coding  DNA, thus the DNA damage repair genes 
are unable to inactivate the occurring mutations. Instability also may result from 
epigenetic mechanisms which may lead to hypomethylation or hyper methylation of 
promoter regions, thus increases gene expression in case of hypomethylation and gene 
silencing in case of hypermethylation. Other factors contribute to genetic instability are 
environmental and dietary factors (Yao and Dai, 2014) 
CIN explains most of human cancers cases, these abnormality could be numerical 
and/or structural changes in the chromosomes (Aboalela et al., 2015).  According to 
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(Thompson and Compton, 2011) structural aberrations of the chromosomes are 
distinctive mark for human epithelial cancer and the end product of impaired genome 
stability mechanism.  Most pathogen etic aberrations are related to deletion or 
amplification of tumor or oncogenes suppressor gene loci  with imbalanced gene 
expression and loss of heterozygosity (Thompson and Compton, 2011).  In epithelial 
cancers related to neoplasms originated in mesenchymal or hematopoietic lineages, 
high chromosomal aberrations are observed.   
 
2.2 Breast cancer  
 
Breast cancer is the abnormal and uncontrolled cellular growth in the tissues of 
the breast. It starts from various parts of the breast, but the majority starts from the ducts 
that carry the milk to the nipple, in this case it is called ductal cancers. It is estimated 
that 55% cases of breast cancer are caused by Invasive ductal carcinoma (IDC) 
(Eheman et al., 2009) Fig (2.1). Another type is the one that starts in the glands that 
produces milk (lobular cancers) Fig (2.1). The growth of tumor is not related to the 
initiate site or the cellular origin of the cancer. However, it differs in term of the biology 




Figure 2.1 : The anatomy of invasive ductal carcinoma an invasive lobular carcinoma  
(Medium.com, 2018). 
 
2.3 Burden of Breast Cancer  
 
In 2012 the total number of diagnosed breast cancer cases was 1.7 million 
among females with total casualties of 521,900 deaths worldwide, 25% of deaths were 
cancer cases and 15% were related to cancer (Nounou et al., 2015). High-income 
Countries such as Australia, America, New Zealand plus Western and Northern parts 
of Europe recorded the highest incidents of breast cancer (Torre et al., 2017). In low 
and middle-income countries (LMIC) countries like sub-Saharan Africa has low 
incidents but high death rates because of the access to treatment is limited and the 
diagnosis stage is late (Jedy-Agba et al., 2016)  In men, of all breast carcinoma incidents 
it accounts about 0.8% to 1% (Gomez-Raposo et al., 2010). However, majority of cases 
in men are positive hormone receptor which means it can show good treatment results 
(Nounou et al., 2015). Male breast tumours are more likely to express progesterone 
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(PR) and estrogen (ER) receptors with overexpression of human epidermal growth 
hormone receptor (HER2) compared to females (Gomez-Raposo et al., 2010). In terms 
of diagnosis, men are diagnosed at older age compared with women (Nounou et al., 
2015). 
 
2.4 Prevalence of breast cancer in Asia 
 
In Asia, breast cancer is considered the most common cancer. The rapid increase in 
cases of breast carcinoma are mainly localized in the undeveloped countries (Youlden 
et al., 2014). Incidents in Asian countries are lower when compared with America and 
Europe, however, the mortality rate in Asia is higher than America and Europe (about 
6-23 per 100,000) (Jemal et al., 2011). Increased of incidence rate was reported in Asia 
among women under 40 years age (Ghoncheh et al., 2016).  
According to the world health organization (WHO), most Asian countries has no 
cancer registration system, thus the incidents rates are higher in reality (Ghoncheh et 
al., 2016). Countries including Egypt, Brazil, Mauritius, Kuwait, Guatemala, Moldova 
and Mexico has increased in mortality rates due to the reduction in breast feeding, 
fertility, bad diet and lifestyle habits (low physical activity and obesity), and exposure 
to exogenous hormones (Ghoncheh et al., 2016). Asian countries such as Japan, China, 
South Korea, Singapore, Philippines, Taiwan and Thailand has registered the highest 
breast cancer cases among Asian countries (Shin et al., 2010).  
Worth noting, in Asia the age of breast cancer diagnosis is between 45-55 years, 
however, in western countries is 55-60 years of age (Ghoncheh et al., 2016). Thus, 
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among young women in Australia and New Zealand the rate of breast cancer is higher 
compared with Asian countries (Liu et al., 2011). 
  Case studies and control studies reported that old age childbirth, early 
menstruation, late menopause and few full-term pregnancies are what causing high 
rates of breast cancer among Asian women (Yanhua et al., 2012).  Standardized death 
rates in Asia differs from country to another, as for countries with high standardized 
death rates including Lebanon, Armenia, Jordan, Pakistan and Syria. While Mongolia, 
China, Bhutan and Nepal has the lowest standardized death rates (Ghoncheh et al., 
2016). However, In many European countries and in US, the mortality rates has been 
reduced because of the introduction of mammography, early detection of the disease, 
progress in treatment and the early detection of small tumours (Ghoncheh et al., 2016). 
Reducing breast cancer mortality rate is improved through the implication of 
factors such as prognosis and early detection of the disease (Rahimzadeh et al., 2014). 
The mortality rates around the world differs from region to another, it is low in the west 
(6 per 100,000) and high in the developing countries (20 per 100,000)  (Ghoncheh et 
al., 2016). 
The reasons why breast cancer is poorly managed in Asia are related to cultural 
and economic status (lack of awareness, lack of appropriate diagnostic equipment, lack 
of treatment facilities, relying on traditional solution and competition in the healthcare 






2.4.1 Prevalence of Breast Cancer in Malaysia  
 
In Malaysia 50% of women are diagnosed with breast cancer before the age of 
50 compared with the western countries, the percentage of women diagnosed before the 
age of 50 is 20%, it because the Malay women present at early stages earlier than the 
women in the west (Yip et al., 2014). According to the National Cancer Registry (NCR) 
the incidents of breast cancer between 2003-2005 were high among the Chinese about 
59.9 per 100 000, as for Indians and Malays the numbers are 54.2 per 100 000 and 34.9 
per 100 000 respectively (Yip et al., 2014). Azizah (2015) reported that statistics of 
breast cancer between 2007-2012 in Malaysia, among Chinese, the cumulative risk of 
breast cancer was high and low among Malay. The lifetime risk among the Malay was 
1 in 35, Chinese was 1 in 22 and among Indians it was 1 in 24. (Figure 2.4.1) shows the 







Figure 2.4.1: The Age-standardized rate (ASR) of breast cancer in the states of 
Malaysia (Azizah, 2015). 
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  In 2012, The International Agency for Research in Cancer (GLOBOCAN) 
reported that the prevalence of breast cancer in Malaysia was 38.7 per 100,000 with 
5410 new cases (Yip et al., 2014). 
Among the south-eastern Asia countries, Malaysia has the highest breast cancer 
mortality rate (18 per 100,000) (Nordin et al.). A population based study reported that 
Malaysia has a median of overall survival time of 68.1 months (Abdullah et al., 2013).   
 
2.5 Subtyping Breast Cancer by its receptor statues 
 
2.5.1 Hormone Receptor-Positive Breast Cancer 
Majority of breast cancer cases are hormone- receptor (HR) positive, which 
account about 80%. Hormone-receptor cancers tends to be slower course compared 
with TNBC and HER2 cancers, and it may express estrogen as well as progesterone 
(Peddi, 2018). ER/PR positive breast tumour means that breast cancer cell have 
estrogen and progesterone receptor, in which these receptors receive signals from 
estrogen and progesterone to start growing (Iqbal and Buch, 2016). ER/PR expression 
in patient’s breast can be significant prediction and it benefits whether the patient will 
respond to endocrine therapy (ET) or not (Iqbal and Buch, 2016).  
2.5.2 HER2-Positive Breast Cancer 
Human epidermal growth factor receptor 2 (HER2) belongs to the family of 
human epidermal receptor proteins. HER2 is a transmembrane tyrosine kinase 
expressed in normal tissues of the breast, placenta, skin, urinary tract and the 
gastrointestinal (Zhu and Verma, 2015). HER2 is involved in the transduction of cell 
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signal, thus it interfere with proliferation, mortality and survival of the cells and it has 
no known ligands gastrointestinal (Zhu and Verma, 2015). 
The percentage of breast cancer cases that shows positive amplification for 
HER2 is about 15%-20%, and has worse outcomes compared with the other breast 
cancer subtypes. The HER2 subtype is biologically aggressive and has short term 
reoccurrence and survival (Zhu and Verma 2015).    
2.5.3 Triple-Negative Breast Cancer (TNBC) 
A type of breast cancer that does not express estrogen, progesterone and HER2 
receptors, hence the name Triple-Negative (Wahba and El-Hadaad, 2015). This type of 
cancer constitute approximately 10% to 20 % of total breast cancer cases (Brouckaert 
et al., 2012). Profiling of gene expressions by microarray showed that approximately 
75% to 80% of TNBCs are basal-like tumours (Badowska-Kozakiewicz and Budzik, 
2016). TNBC is more severe than normal breast cancer because it has the worse 
prognosis with high risk of re-occurrence and death (Saraiva et al., 2017). In fact, those 
who are treating from TNBC with standard taxane and/or anthracycline based 
chemotherapies have early relapse, and those who had been diagnosed with the disease 
within 1-3 years their condition may develop into visceral metastasis. The survival rate 
of patients with metastatic TNBC is low and it does not exceed 12 months even if they 
are responding to chemotherapy treatment (Diana et al., 2018).  
The standard treatment method for TNBC is chemotherapy despite the novel 
drug discoveries made twenty years ago (Diana et al., 2018).     
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2.5.3.1 Classification of Triple-Negative Breast Cancer (TNBC) 
The first classification of TNBC was reported by (Ahn et al., 2016) using DNA 
microarray as a mean to detect the differences on gene expression. They grouped TNBC 
into five types: normal breast-like, basal-like, luminal A, luminal B and HER2-
enriched. Some scientists classified TNBC into six subtypes: basal-like 1 (BL1), basal-
like 2 (BL2), mesenchymal (M), immunomodulatory (IM), mesenchymal stem-like 
(MSL) and immunomodulatory (IM). Other scientist divided it into four subtypes: 
basal-like/immune activated (BLIA), basal-like/immune-suppressed (BLIS), 
mesenchymal (MES) and Luminal Androgen Receptor (LAR) (Lehmann et al., 2011)  
The terms TNBC and basal-like are used as synonymous in some occasions, 
although 75% to 80% of TNBCs are basal-like but it is important to note that not all 
TNBC cases are diagnosed as basal-like by gene expression profiling and not all basal-
like cases are TNBC when diagnosed with IHC (Lehmann and Pietenpol, 2014).  
 
2.5.3.1.1 Basal-Like Subtypes (BL1 and BL2) 
According to Lehmann et al. basal-like 1 (BL 1) subtype enriched with 
pathways and has high content of cell-cycle genes which are important in the process 
of repairing DNA damages, leading to high expression levels of Ki-67 and cellular 
proliferation (Lehmann et al., 2011). The second subtype (BL2) express high levels of 
signalling receptor tyrosine kinase, like insulin growth factor receptor (IGF1R), 
epithelial growth factor (EGF) and MET pathways plus cell signalling of 
gluconeogenesis and glycolysis (Diana et al., 2018).  
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Recent sub-classification was done by (Burstein et al., 2015) were he divided 
BL subtypes into two cluster BLIS 1 and BLIS 2. The BLIS 1 cluster displays 
downregulation in cellular immunity cells ( T cells and B cells) as well as immune-
regulating natural killer cells and cytokines pathways (Hubalek et al., 2017). Due to its 
cellular immunity differentiation, cellular communication of innate and adoptive 
immunity and low expression of molecules that controls the antigen presentation, BLSI 
1 has the worse prognosis. But its expression of transcription factors of the SOX family 
is uniquely present. The BLIS 2 cluster has characteristics similar to 
immunomodulatory subtype (IM) (Lehmann et al., 2011) 
Approximately all types of TNBC cell lines with known BRCA1 and BRCA 2 
abnormalities have correlating patterns of gene expression with basal-like subtype 
(Stefansson et al., 2009). 
 
2.5.3.1.2 ImmunoModulatory (IM) Subtype 
IM subtype has a high content of factors implicated in cellular immunity 
processes (cellular immunity signalling) (Hubalek et al., 2017). IM immune signalling 
genes significantly correlates with a gene signature found in medullary breast cancer. 
IM subtype exhibits upregulation in genes that controls the cellular function of T, B, 
and natural killer cells, in contrast with BLIS. In terms of prognosis, IM has the best 
prognosis because it expresses high levels of STAT genes and displays STAT 




2.5.3.1.3 Mesenchymal Stem-Like (MSL) and Mesenchymal (M) subtypes  
Both MSL and M subtypes have high content of pathways and components 
participates in cell motility, cellular differentiation and interaction of extracellular 
receptor. However, what makes MSL subtype uniquely different from M subtype are 
the processes and gene representing components which are linked to growth factor 
signalling pathways that include EGFR, inositol phosphate metabolism, PDGF, G-
protein coupled receptor, calcium signaling, ERK1/2 signaling and adipocytokine 
signalling as well as ABC transporter (Hubalek et al., 2017). Moreover (Burstein et al., 
2015) reported that MSL subtype express genes that are only found in adipocytes 
(ADIPOQ, PLIN1) and osteocytes (OGN), plus high expression of growth factors (IGF-
1) is also expressed by this particular subtype. 
 
2.5.3.1.4 Luminal Androgen Receptor (LAR) Subtype 
LAR subtype differs from the rest of TNBC subtypes for being ER-negative 
despite the fact that its genes are enriched heavily with pathways regulated by hormones 
such as androgen/estrogen metabolism, steroid synthesis and porphyrin metabolism 
(Hubalek et al., 2017). LAR tumours shows ER, AR, ErbB4 signalling and prolactin 
positive IHC staining but negative ERα. LAR expresses estrogen-regulated genes 
(GATA3, XBP1, PGR and FOXA) and ESR1 (ERα  encoding gene) as shown by gene 
expression profiling report. Thus, ER activation is present in these ER-negative 
tumours (Burstein et al., 2015). This is why these tumours are called ER-negative as 
defined by IHC staining because only 1% of these tumours express low levels of ER-
protein (Burstein et al., 2015). LAR subtype consist of AR-driven tumours because AR 
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is highly expressed at mRNA levels of LAR tumours, in fact, LAR tumours express AR 
9 times greater than the other remaining subtypes of TNBC as shown by IHC staining. 
Plus LAR tumours express captivators and AR targets (Hubalek et al., 2017). 
 




With advancing in age the risk of developing breast cancer increases. Database 
acquired from the Surveillance, Epidemiology and End Result (SEER) shows that 
women in the united states developing  cancer of the breast from birth to 39 years of 
age 1 in 8: 1 in 202, from 40-59 is 1 in 26, and 1 in 28 from 60-69 years (Siegel et al., 
2013)  
2.6.2 Personal history  
 
An important factor of risk getting breast cancer is personal history. Women 
with breast cancer has the chance of second reoccurrence of cancer in the same breast 
(ipsilateral or contralateral breast cancer (Geurts et al., 2017).  Methcronous 
contralateral breast cancer is considered a common cancer in amongst survivors (Curtis 
RE, 2006) other factors linked with reoccurrence of breast cancer such as young age, 






2.6.3 Family history 
 
 If there is a member in the family who has a history of breast cancer the chances 
of a women developing the disease are high.  A study done by The Nurse Health, a 
mother diagnosed before she was 50 years of age her daughter had an adjusted risk of 
1.69 and another mother diagnosed at age of 50 or older her daughter had a risk of 1.37 
comparing with a woman with no family history of the disease. Between siblings an 
increase of 1.66 risk in women if she has a sister diagnosed with breast cancer before 
the age of 50 compared with patients who do not have family history (Colditz et al., 
2012). Increasing number of first-degree relatives with breast cancer diagnosed at a 
young age below 50 shows that women were associated with high risk of the disease. 
Those who have one, two or three affected relatives increases the chances by 1.80, 2.93 
and 2.90 respectively compared with those who don’t have affected relatives (Lancet, 
2001). 
 
2.6.4 Breast feeding  
 
Breast feeding has protective effect against the development of breast cancer 
evidence suggests. It lowers the levels of endogenous sex hormones and delays the 
regular ovulatory cycles. The estimated reduction of breast cancer during breast feeding 
is 4.3% for each year (Lancet, 2002). 
 
2.6.5 Breast pathology  
 
Breast cancer is highly associated with proliferative breast disease.  
Proliferative diseases such as ductal hyperplasia, intraductal papillomas, sclerosing 
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adenosis and fibroadenomas without atypia confirm a small risk increase of developing 
breast cancer by approximately 1.5-2 times (Hartmann et al., 2005). Ductal and lobular 
hyperplasia will increase the risk substantially. Proliferative disease with atypia will 
increase the risk by 4.3 (Dupont et al., 1993). 
 
2.6.6 Testosterone  
 
High levels of sex hormone will increase the chances of breast cancer in both 
pre and postmenopausal women. In postmenopausal women high levels of circulating 
will increase the risk by 2.86-3.28 (Sieri et al., 2009)  
 
2.6.7 Age at menopause  
 
Breast cancer is linked with delayed menopause. Every year of delay the risk 
increases by 3% and every 5 years the risk is 17% (Surakasula et al., 2014).  
 
2.6.8 Exposure to exogenous hormones  
 
Studies have demonstrated the association of hormone replacement therapy 
(HRT) with breast cancer risk (Hou et al., 2013). A meta-analysis international 
examination for breast cancer showed that women who are at menopause and did not 
use HRT, their risk factor increased by 1.028 each year as they grow older compared 
with HRT users (Lancet, 1997). A randomized control study done by the Woman’s 
Health Initiative in which they used estrogen and progestin in postmenopausal women 
with healthy uterus increased the risk of the disease, delayed its detection a diagnosis 
plus increased the mortality. In difference, women with no uterus at postmenopausal 
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who used estrogen alone did not interfere with the detection of breast and significantly 
decreased the risk (Passarelli et al., 2013). Other factors related to HRT such as duration 
and timing of the therapy are associated with breast cancer. Less than five years use of 
combined HRT is related to high risk whereas short term use of combined estrogen-
progestin therapy has not shown any significant increase (RR = 1.023 per year) 
(Chlebowski et al., 2013).  
 
2.6.9 Genetics related to heredity  
 
2.6.9.1 The BRCA genes and its mutations  
The location of BRCA1 gene is on the chromosome number 17, while BRCA2 
is located on the chromosome number 13 (Cavanagh and Rogers, 2015). The BRCA 
genes work by suppressing cellular growth and production of tumour suppresser gene 
proteins (TSG) (Mehrgou and Akouchekian, 2016). The number of amino acids found 
in BRCA1 is about 1863 with reported 300 mutations causing disease, while BRCA2 
has 3418. (Mehrgou and Akouchekian, 2016). TSGs act as an anti-oncogene by 
repairing damaged DNA and ensure its genetic materials are well preserved, thus any 
problems with these proteins will eventually lead to unrepaired DNA strands leading to 
the occurrence of mutations (Mehrgou and Akouchekian 2016). 
BRCA1/2 genes are autosomal dominant and highly expressed in breast and 
ovarian cancers (Ayub et al., 2014). Any abnormalities or changes occur one or both 
BRCA genes increases the risk of developing prostate, ovarian and breast cancers 
(Mehrgou and Akouchekian, 2016). Mutations such as small deletion, small insertion, 
nonsense mutation, premature transcription mutation, missense mutation, and splicing 
troubles are considered to be the most common types of mutation that occur to the 
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BRCA genes (Mehrgou and Akouchekian, 2016). Splicing spots mutations can lead to 
the production of non-functional proteins, insertion and deletion mutations can produce 
frame shift (Neamatzadeh et al., 2015).  
 
2.6.9.2 The role of BRCA1/2 in the formation of cancer  
Nearly 5-10% of breast cancer cases caused by hereditary and the reason behind 
it are the BRCA mutations in the western part of the world (Peshkin et al., 2010). Meta-
analysis study reported that BRAC1/2 mutations contribute to lifetime risk of devolving 
cancer of breast by a percentage of 40-57% and lifetime risk of developing cancer of 
ovary by a percentage of 18-40% (Chen and Parmigiani, 2007). Breast cancer patients 
who are diagnosed at the age of 25 years and carrying BRCA1/2 mutations have 50% 
risk of devolving contralateral breast cancer (Peshkin et al., 2010). Approximately 80% 
of BRCA1 mutation are associated with TNBC (Turner and Tutt, 2012). 
BRCA1 gene encodes a protein responsible for repairing damaged DNA (Godet 
and Gilkes, 2017). BRCA1 protein repairs damaged DNA through several cellular 
processes including the creation of heterochromatin on the chromosome X, regulating 
the transcription of genes associated with DNA repair, attaching ubiquitin with other 
proteins through a process called ubiquitination and repairing broken double stranded 
DNA (Godet and Gilkes, 2017).  During DNA damage and cell cycle responses, 
BRCA1 binds with RAD51, TP53 and BRCA2 (Godet and Gilkes, 2017). Non-
functional BRCA1 protein can force cells not to undergo cell cycle arrest at the G2 
phase following damaged DNA and can cause deficit in transcription-coupled repair 
(Godet and Gilkes, 2017). Worth noting that BRCA1 allows proteins that repair 
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damaged DNA to the damage sites by interacting with γH2AX (Godet and Gilkes 
2017).  
BRCA2 gene responsible for encoding protein which has the same function as 
BRCA1 protein (Petrucelli et al., 2010). Cells that lacks BRCA2 can cause unexpected 
abnormalities in the chromosomes (ri-radials, quadri-radials, and double-stranded) and 
shortfall in the separation of chromosomes (Godet and Gilkes 2017). 
 
2.6.10 Radiation  
 
Exposing radiation increase the chances of cancer in general. Various sources 
of radiation such as medical treatment or nuclear explosion elevates the risk of breast 
cancer. Radiation of chest wall to treat cancer in children increase the risk depending 
on the dose of radiation (Henderson et al., 2010). Children who are receiving treatment 
for Hodgkin’s disease develop the risk of getting breast cancer by (RR = 7) (Henderson 
et al., 2010). Nuclear radiation incidents happened in japan during World War 2 led to 
the development of breast in Japanese women (Katayama and Narimatsu, 2016) at age 
younger than 35 years. In Belarus and Ukraine the Chernobyl reactor accidents led to 
the increased incidents of breast cancer especially in young women (Pukkala et al., 
2006).    
2.7  Screening  
 
2.7.1 Clinical breast examination and breast self-examination  
 
Breast self-examination (BSE) is a questioned method because it did not 
demonstrate any benefits of mortality decreasing (Kosters and Gotzsche, 2003), but 
most clinician urge women to examine their breast monthly through breast self-
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examination (BSE) so that they will be aware of their normal breast (McCready T, 
2005). As for clinical breast examination (CBE), the NCCN recommend women who 
are younger than 40 years of age to perform both examinations (BSE and CBE) 
annually (Bevers et al., 2009).  
2.7.2 Mammography 
 
In the 1960s the technique exhibited good results in terms of mortality decrease. 
The first randomized control trials comparing between clinical examination and 
mammography screening was done during that time. The results favored 
mammography screening and showed a decrease in mortality in one third of the 
experimented group. However, in breast cancer women aged between 40-49 years there 
is still debate concerning mortality in that particular subset (Shapiro et al., 1985). In 
women aged 40 to 70 years, a contemporary randomized control trials have showed 
mammography screening benefits (Nelson et al., 2009). A review done by the Cochrane 
in 2013 suggest that there is undue stress and uncertainty in the face of false positive 
due to routine mammography with increase in lumpectomies and mastectomies but no 
decrease in mortality (Gotzsche and Jorgensen, 2013). In screening for the disease, 
overestimation of survival time among screening-detected cases in comparison with 
clinically detected cases when the true survival time remains unchanged (Lead time) 
and overestimation of screening-detected cases which is cause by the slow progressed 
cases may never be clinically relevant (length time) are problems associated with 




2.7.3 Magnetic resonance imaging 
MRI plays a significant role in diagnosing, assessing and managing breast 
cancer in women. It has high sensitivity of 0.77-0.79 compared to sensitivity of 
mammography and less specific than mammography with 0.86-0.89 specificity while 
mammography has as specificity of 0.95 in cancer detection (Warner et al., 2008). 
Systemic review to measure the sensitivity and specificity of both MRI and 
mammography, both showed a combined sensitivity and specificity of 0.94 and 0.77 
respectively (Warner et al., 2008). NCCN advice patients with increasing breast cancer 
developing risk (< 20%) to perform yearly MRI and mammography checkup starting at 
the age of 25. Patients who underwent breast augmentation and the mammography 
imaging is unclear, MRI is the best option for examination or for those who have 
equivocal findings on other imaging modalities.    
2.7.4 Ultrasound 
Several studies suggested that patients with high risk of disease and also have 
dense breast tissue, the use of ultrasound screening can give false positive results (Berg 
et al., 2008). Clinicians who suspect in a certain case use ultrasound screening as a 
replacement to traditional method (mammography) especially in cases with dense 
breast tissue because the use of mammography in these cases gives low sensitivity 
(Kelly et al., 2010). Studies have shown that the use of ultrasound followed by 
mammography to detect progressive breast cancer gives slight benefits in patients with 





2.8 Diagnosis of breast cancer  
 
2.8.1 Physical and history examination  
The physical examination of the patient’s breast like changes in the asymmetry 
of the nipples, the appearance of dimpling, erythema and peaud' orange and the 
formation of mass in the breast are taken into consideration as it indicates the formation 
of breast cancer   
Clinical history focuses on the assessment of cancer risk and the absence and 
presence of breast cancer symptoms. The clinical history includes information about 
the suspected patients such as menopausal statues, previous pregnancies, age at 
menarche, oral contraceptive usage and family history of breast cancer 
. 
2.8.2 Diagnosis through imaging 
 
2.8.2.1 Mammography  
In terms of breast cancer detection, mammography still the gold standard 
method in the diagnosis of breast cancer. Women who have palpable mass or breast 
cancer symptoms, diagnostic mammograms are used (Drukteinis et al., 2013). 
According to The breast imaging reporting and database system (BI-RADS) malignant 
masses are described as oval, round, irregular or lobular while benign masses are 
different in terms of size (larger), lucent centre and round(Smetherman, 2013).  
2.8.2.2 Magnetic resonance imaging (MRI) 
 
MRI plays a critical role in diagnosis and management of breast cancer 
(Radhakrishna et al., 2018). MRI is used when there are limitations in using 
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mammography especially in patients underwent breast augmentation (saline and 
silicone implants) or silicone injections (Ojeda-Fournier and Comstock, 2009). Other 
limitations such as knowing the disease extent from first diagnosis (muscular invasion 
by the disease), screening of asymptomatic patients with high risk of breast cancer and 
inclusive findings evaluation (Kilic et al., 2012).  
2.8.2.3 Ultrasound 
Ultrasound examination for the breast could be done when there are certain 
cases like unavailability of MRI, axillary lymphadenopathy suspicion, clinical 
abnormality at the age of 40 (pregnant or lactating women), retraction of the skin newly 
inverted nipple or breast implants affecting MRI (Evans et al., 2018). 
2.8.3 Diagnosis through prognostic indicators 
 
2.8.3.1 Statues of progesterone and estrogen receptors  
ER and PR tests must be performed on all cases of invasive breast carcinoma 
(Duffy et al., 2017). The assessment of ER and PR is achieved through staining of 
tissues using immunohistochemistry (IHC) technique (Sinn et al., 2017). IHC identifies 
in situ or invasive cancer (Zaha, 2014). In order to achieve positive results, 1% of cancer 
cells are required. While negative results are interpreted when there is less than 1% of 
cancer cells in the tissue (Hammond et al., 2010). 
2.8.3.2 Assessment of HER2 protein expression and gene amplification 
Generally, HER2 protein expression is evaluated using IHC staining (Hicks and 
Schiffhauer, 2011). However, if the result of IHC is ambiguous another method 
compensate IHC assay which is Fluorescence in situ hybridization (FISH) assay 
(Zoppoli et al., 2017). HER2 is an indicator for both node-positive and node-negative 
